Is the Cochlear share price a buy?

The Cochlear limited (ASX: COH) share price has fallen almost 8% in August. Does this put it in the buy zone?

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Cochlear limited (ASX: COH) share price has fallen almost 8% in August. This is a positive sign for those of us waiting for an opportunity to buy COH shares. At $202.17 per share (at the time of writing), I still think Cochlear shares are too expensive to buy, however; if the current trend continues, I'm hopeful there might be an opportunity to buy in the not too distant future.

Cochlear's performance

Cochlear has performed extremely well over the past decade. It has averaged a return on equity of more than 35% and has almost doubled its earnings. This has been achieved while maintaining a relatively low amount of debt and while consistently paying out at least 69% of its earnings as dividends.

The company generates 88% of its revenue from the sale of its cochlear implants. These implants are considered to be an industry leading product and are used to treat hearing loss. Cochlear aims to spend 12% of its revenue on R&D, which should help it in maintaining its current position as a market leader.

Is Cochlear a buy? 

I expect Cochlear to continue to perform exceptionally well over the long-term. However, this view also appears to be the view of the market with COH shares trading at a price-to-earnings ratio of 46 times.

I believe $170 is a rough estimate of fair value for Cochlear shares at the moment, but there is no way of knowing if the Cochlear share price will ever reach this level. Nevertheless, I would prefer to wait patiently and potentially miss out rather than risk paying too much. Paying a price above fair value could mean weak investor returns, despite owning a highly successful company.

Cochlear is due to release its full-year results tomorrow, so I'll be watching with interest what impact it has on the share price.

Foolish takeaway

In my view, it is not the right time to buy Cochlear shares, but I would strongly consider investing in the future at a lower price. CSL Limited (ASX: CSL) is another biotech company I would love to own but again, its share price seems overvalued. This means that I will be waiting patiently before investing in the biotech space. I believe waiting for a cheap price is a far better approach than investing simply due to the fear of missing out on short-term gains.

Mitchell Perry has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of Cochlear Ltd. and CSL Ltd. The Motley Fool Australia has recommended Cochlear Ltd. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »